Rocket Pharma ex-officer plans $22.7K stock sale

ROCKET PHARMACEUTICALS, INC.

Rhea-AI Filing Summary

ROCKET PHARMACEUTICALS, INC. (RCKT) is the issuer of common stock for which former officer John Militello has filed a notice under Rule 144 to sell 6,857 shares through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate value of $22,730.96 as of September 14, 2026.

The shares to be sold were acquired on September 10, 2026 through restricted stock vesting as compensation from the issuer, and the filing notes that the sale includes an amount necessary to cover a tax obligation from settlement of a vested equity award distribution. In the preceding three months, Militello reported sales of 1,252 shares for $4,233.51 on August 18, 2026 and 8,923 shares for $30,367.65 on September 11, 2026.

Key Figures

Shares planned for sale: 6,857 shares Aggregate market value of planned sale: $22,730.96 Acquisition date of shares: September 10, 2026 +3 more

6 metrics

Shares planned for sale 6,857 shares Common stock to be sold under Rule 144 through Fidelity Brokerage Services LLC

Aggregate market value of planned sale $22,730.96 Value of 6,857 RCKT shares as of planned NASDAQ sale on September 14, 2026

Acquisition date of shares September 10, 2026 Date the 6,857 shares were acquired via restricted stock vesting as compensation

Prior sale on August 18, 2026 1,252 shares for $4,233.51 Common stock sold by John Militello during the past three months

Prior sale on September 11, 2026 8,923 shares for $30,367.65 Common stock sold by John Militello during the past three months

Date of notice September 14, 2026 Date the Form 144 notice was signed and filed

Key Terms

Rule 144, Restricted Stock Vesting, equity award distribution, Former Officer

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting financial

"Common | 09/10/2026 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

equity award distribution financial

"resulting from the settlement of a vested equity award distribution."

Former Officer other

"Former Officer 144: Securities Information"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for ROCKET PHARMACEUTICALS, INC. (RCKT)?

It discloses that former officer John Militello plans to sell 6,857 shares of RCKT common stock under Rule 144 through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate value of $22,730.96 as of September 14, 2026.

How many RCKT shares is John Militello planning to sell under this Form 144?

John Militello is planning to sell 6,857 shares of ROCKET PHARMACEUTICALS, INC. common stock, with an aggregate value of $22,730.96 as reported for the planned NASDAQ sale dated September 14, 2026.

How did John Militello acquire the RCKT shares being sold?

The 6,857 RCKT shares were acquired on September 10, 2026 through restricted stock vesting as compensation from the issuer, ROCKET PHARMACEUTICALS, INC.

What prior RCKT stock sales has John Militello reported in the last three months?

He reported selling 1,252 shares for $4,233.51 on August 18, 2026 and 8,923 shares for $30,367.65 on September 11, 2026.

Why does the Form 144 mention tax obligations for the RCKT share sale?

The remarks state that the sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution related to the restricted stock vesting.

Which broker is handling the planned RCKT share sale for John Militello?

The planned sale of 6,857 RCKT shares is to be handled by Fidelity Brokerage Services LLC, with the shares listed for trading on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 03:25 PM Accepted by SEC EDGAR 09/14/2026 - 03:25 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001662170
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ROCKET PHARMACEUTICALS, INC.
SEC File Number	001-36829
Address of Issuer	350 FIFTH AVENUE SUITE 7530 NEW YORK NEW YORK 10118
Phone	646-440-9100
Name of Person for Whose Account the Securities are To Be Sold	Militello John
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	6857	22730.96	109774597	09/14/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/10/2026	Restricted Stock Vesting	Issuer			6857	09/10/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
John Militello 9 Cedarbrook Drive Cranbury NJ 08512	Common	08/18/2026	1252	4233.51
John Militello 9 Cedarbrook Drive Cranbury NJ 08512	Common	09/11/2026	8923	30367.65

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	09/14/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Adam Gehring, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for John Militello
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)